SARS-CoV-2靶向TCR-T (因诺免疫)(TCR-T cell treatment of COVID-19 (Innovation Immunotechnology))

概要

基本信息

药物类型

TCR-T细胞疗法

别名

SARS-CoV-2 Targeted TCR-T (Innovation Immunotechnology)

靶点-

作用方式-

作用机制-

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

深圳因诺免疫有限公司

在研机构

深圳因诺免疫有限公司

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 SARS-CoV-2靶向TCR-T (因诺免疫) 相关的临床结果

登录后查看更多信息

100 项与 SARS-CoV-2靶向TCR-T (因诺免疫) 相关的转化医学

登录后查看更多信息

100 项与 SARS-CoV-2靶向TCR-T (因诺免疫) 相关的专利（医药）

登录后查看更多信息

1

项与 SARS-CoV-2靶向TCR-T (因诺免疫) 相关的文献（医药）

2022-11-01·International Immunopharmacology

Identification and assessment of TCR-T cells targeting an epitope conserved in SARS-CoV-2 variants for the treatment of COVID-19

Article

作者: Liu, Fenglan ; Li, Bin ; Peng, Kaiqi ; Nielsen, Morten ; Zhou, Hong ; Xu, You ; Wang, Mingjun ; Deng, Lijuan ; Tian, Geng ; Ma, Yipeng ; Qiao, Dongjuan

BACKGROUNDCoronavirus disease 2019 (COVID-19) continues to be a major global public health challenge, with the emergence of variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current vaccines or monoclonal antibodies may not well be protect against infection with new SARS-CoV-2 variants. Unlike antibody-based treatment, T cell-based therapies such as TCR-T cells can target epitopes that are highly conserved across different SARS-CoV-2 variants. Reportedly, T cell-based immunity alone can restrict SARS-CoV-2 replication.METHODSIn this study, we identified two TCRs targeting the RNA-dependent RNA polymerase (RdRp) protein in CD8 + T cells. Functional evaluation by transducing these TCRs into CD8 + or CD4 + T cells confirmed their specificity.RESULTSCombinations of inflammatory and anti-inflammatory cytokines secreted by CD8 + and CD4 + T cells can help control COVID-19 in patients. Moreover, the targeted epitope is highly conserved in all emerged SARS-CoV-2 variants, including the Omicron. It is also conserved in the seven coronaviruses that infect humans and more broadly in the subfamily Coronavirinae.CONCLUSIONSThe pan-genera coverage of mutant epitopes from the Coronavirinae subfamily by the two TCRs highlights the unique strengths of TCR-T cell therapies in controlling the ongoing pandemic and in preparing for the next coronavirus outbreak.

100 项与 SARS-CoV-2靶向TCR-T (因诺免疫) 相关的药物交易

登录后查看更多信息